PARACELSIAN ANNOUNCES BOARD RESIGNATIONS AND INVESTMENT


ITHACA,  N.Y., Jan.14  /PRNewswire/ -- Paracelsian,  Inc. (Nasdaq:  PRLN - NEWS)
announced today that it has signed an agreement with Biomar International, Inc.,
that provides Paracelsian with financing of up to $1.2 million. Biomar is making
an  initial  investment  of  $500,000,  with an option  to invest an  additional
$520,000.

Under the  terms of the  agreement  signed  today,  all  existing  Directors  of
Paracelsian  have  resigned.   Six  of  the  seven  resignations  are  effective
immediately.  T. Nelson Campbell,  Chairman of Biomar, has been appointed to the
Board of Paracelsian, effective immediately.

In compliance with SEC regulations,  the resignation of the remaining members of
the old Board of Paracelsian  becomes  effective  with the  appointment of a new
slate of  Directors  selected by Biomar.  Announcement  of the new  Directors is
expected within a few days.  Their  appointments  will become  effective 10 days
after shareholder notification.

Prior to  their  resignations,  Paracelsian's  Board of  Directors  approved  an
agreement  with  Keith A.  Rhodes,  the  Company's  former  President  and Chief
Executive Officer, resulting in the return of his 705,000 shares of common stock
to the Company.  The Board also agreed to forgive a loan  extended to Mr. Rhodes
for the purchase of the shares.

"The  first step to  restoring  shareholder  value is to  rebuild  Paracelsian's
credibility  with the  investment  community,"  said Timothy J. Smith,  Biomar's
President and Chief Executive Officer.  "Because we recognize that this can only
happen  with a clean  slate,  we made this a  condition  of our  investment.  In
addition  to  establishing  new  initiatives,   the  new  Board  will  focus  on
implementing those ideas that stimulated so much earlier investor interest."

Biomar International,  in Chapel Hill, North Carolina, is developing statistical
algorithms  that  utilize  information  on blood and urine based  biomarkers  to
assess  individual  health  and  status  and to  predict  the  onset of  chronic
degenerative   diseases.   Biomar's   technology  --  being   developed  from  a
longitudinal  study in China -- is expected to provide a more  powerful tool for
assessing the efficacy of medical interventions,  including the use of nutrition
and natural products.

Paracelsian  is a company  engaged  in the  discovery  and  characterization  of
uniquely  beneficial  constituents of herbs and other  botanicals for use in the
natural products and pharmaceutical  industries. Its core technology consists of
immuno-based and cell-based signal transduction assays.